Detailed Abstract
[BP Oral Presentation 3 - Biliary & Pancreas (Biliary Disease/Surgery)]
[BP OP 3-6] ROLE OF ADJUVANT CHEMOTHERAPY AFTER HEPATIC RESECTION FOR PATIENTS WITH INVASIVE INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT (IPNB)
Pun PUGKHEM 1, Vor LUVIRA 1, Khanisara KRAPHUNPONGSAKUL 1, Attapol TITAPUN 1, Tharatip SRISUK 1, Theerawee TIPWARATORN 1, Suapa THEERAGUL 1, Apiwat JAREARNRAT 1, Vasin THANASUKARN 1, Supot KAMSA-ARD 2, Ake PUGKHEM 1, Chawalit PAIROJKUL 3
1 Department of Surgery, Faculty of Medicine, Khon Kaen University, Thailand, 2 Department of Epidemiology And Biostatistics, Faculty of Public Health, Khon Kaen University , Faculty of Medicine, Khon Kaen University, Thailand, 3 Department of Pathology, Faculty of Medicine, Khon Kaen University, Thailand
Background : Intraductal papillary neoplasm of the bile duct (IPNB) is acknowledged as a unique entity. Although the role of postoperative adjuvant chemotherapy for cholangiocarcinoma is well-established, there are no reports indicating a survival benefit of adjuvant chemotherapy specifically targeting IPNB. This study represents the first demonstration of the relationship between adjuvant chemotherapy and the survival rates of patients with IPNB.
Methods : We retrospectively reviewed medical records of 360 patients who were diagnosed with invasive IPNB underwent hepatic resection between January 2007 and December 2022. The patients were divided into those (n = 148; 41.11%) who received adjuvant chemotherapy (CMT1) and those (n = 212; 58.89%) who did not (CMT0). Patients survival was analyzed to determine its effect using the Kaplan-Meier method with log-rank test and Cox proportional hazard model.
Results : Demographic and operative variables were comparable between two groups. For the patients with no lymph node metastasis, there was no difference in survival outcome between two groups (P= 0.3). For patients with lymph node metastasis, the median overall survival time was significantly greater in the CMT1 group than CMT0 group (671 vs 479 days, p = 0.012). The 1-, 3-, and 5-years overall survival rate in CMT1 were 80.8, 33.5 and 18.9% compared to CMT0 that were 53.9, 13.5, and 5.4% respectively.
Conclusions : Postoperative chemotherapy may provide survival benefit in the patients with lymph node involvement.
Methods : We retrospectively reviewed medical records of 360 patients who were diagnosed with invasive IPNB underwent hepatic resection between January 2007 and December 2022. The patients were divided into those (n = 148; 41.11%) who received adjuvant chemotherapy (CMT1) and those (n = 212; 58.89%) who did not (CMT0). Patients survival was analyzed to determine its effect using the Kaplan-Meier method with log-rank test and Cox proportional hazard model.
Results : Demographic and operative variables were comparable between two groups. For the patients with no lymph node metastasis, there was no difference in survival outcome between two groups (P= 0.3). For patients with lymph node metastasis, the median overall survival time was significantly greater in the CMT1 group than CMT0 group (671 vs 479 days, p = 0.012). The 1-, 3-, and 5-years overall survival rate in CMT1 were 80.8, 33.5 and 18.9% compared to CMT0 that were 53.9, 13.5, and 5.4% respectively.
Conclusions : Postoperative chemotherapy may provide survival benefit in the patients with lymph node involvement.
SESSION
BP Oral Presentation 3
Room 6 3/27/2025 3:30 PM - 4:30 PM